J&J plans divestments after EU conditionally approves Guidant takeover
This article was originally published in Clinica
Johnson & Johnson has finally crossed the halfway mark in its ongoing bid to take over rival Guidant. The healthcare conglomerate received the go-ahead from the EU on August 25 to purchase Guidant for the negotiated price of $25.4bn, on condition that J&J divested certain overlapping businesses.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.